When the label changes, every live promotional piece built on the old text is found, decided and fixed
When a label changes, every live piece built on the old text is found and fixed.
See one case, screen by screen ↓A supplement is approved and the USPI changes. Somewhere in the detail aids on rep iPads, the CRM email templates, the HCP and patient websites, the media agency’s placements, the social scheduler, the print warehouse and the speaker bureau sit pieces built on the old text. A new warning can turn an approved claim into one the label now contradicts, and FDA expects a statement of intent to comply within days of the approval letter.
Most of the first week goes on finding those pieces. Someone reads the redline, works out which claims-library entries it touches, then searches each channel by keyword — and misses the detail aid that says the same thing in its own words, or the banner with the old number inside an image. Then come the tasks in every system, the agency briefs, and the chasing: a withdrawal is only done when the piece is off every iPad and every printed copy is back.
Estimated split for one label change across nine channels, by hand and with the solution. Revisions through MLR take longer and are not included.
Six specialist agents compare the labels, search every channel and follow each piece through; the regulatory advertising lead decides.
Veltrimab’s USPI Rev. 10/2026 was approved on Oct 2 with a new liver-injury warning. It is day 5. Here is what happens next, screen by screen, in the working solution.
Dana opens the impact map: 312 live pieces checked in nine channels, 87 impacted — 9 to withdraw, 46 to revise, 32 with a safety text update — and 62 still live on the old label. Four withdraw-now pieces wait for her decision, due Oct 9. The other 225 need no change: they use the shared safety information module, updated centrally on Oct 3.
Agents at work: “Inventory searcher matched 4 pieces by meaning that a keyword search misses — ‘no lab tests needed between visits’.”
Rev. 03/2026 against Rev. 10/2026: 41 pages, six changes, from a new ulcerative colitis indication (Low) to the new §5.4 hepatotoxicity warning (Critical). Both passages sit side by side, word for word. The claims library shows what the warning changes: CL-VEL-031, “No routine laboratory monitoring is required”, is retired, and Important Safety Information v03/2026 is replaced by v10/2026.
“Any ‘no lab monitoring’ claim is now contradicted by safety information, and safety text built into a piece must carry the new warning with prominent disclosure.”
Dana presses Find every piece. The claim mapper finds 9 claims-library entries that rely on changed text. The inventory searcher reads 312 live pieces in nine channels by exact text, changed numbers, old references and meaning. The impact classifier sorts them: 87 impacted, 13 of them found by meaning alone.
Task writer: “20 proposals waiting for Dana Okafor — nothing opens until you decide.”
“Starting and staying on Veltrimab”, P-0412, slide 4 of 12: “No lab tests needed between visits.” The new label requires liver enzymes and bilirubin at baseline and at Weeks 4, 8 and 12, so the classifier proposes Withdraw now, with a confidence of 97. The wording differs from the claims library — it was found by meaning. A second flag on the same slide, “Before the first dose: test for TB”, is proposed for revision against §2.1.
Every flag cites both sides: the text in the piece and the label passage that changed.
The piece is on 412 rep iPads, linked to the CRM template “Starting your patients” (sent 1,284 times in 30 days), and printed as a leave-behind — 4,180 copies in stock, about 2,020 with reps. Dana keeps the proposal and signs: her name, password and the meaning, “I approve withdrawing ‘Starting and staying on Veltrimab’ from every channel”, recorded with the time and the cited passages.
The content system expires US-VEL-26-0412 v3 so it cannot be used or ordered. Rep iPads drop it at the next sync — 398 of 412 so far. The CRM template is deactivated, the field recall reaches 37 of 96 reps, and the brand manager decides whether a revised version is needed. Each line turns Confirmed only when its system reads back.
A withdrawal is confirmed only from a read-back — never from a task being closed.
Withdrawals out of use: 6 of 9. Safety text updated: 20 of 32, plus 225 through the shared modules. Revisions: 12 in MLR, 22 with agencies, 12 to brief, due Nov 1. Every channel shows its pieces still on the old label, and the field recall is tracked region by region — 61 of 96 reps confirmed.
Under 21 CFR 601.12(a)(4): 9 pieces withdrawn from use by Oct 9, 257 with safety information updated by Oct 16, 46 revised and resubmitted on Form FDA 2253 by Nov 1 — with prominent disclosure of the new hepatotoxicity warning. Every count links to its pieces. Dana signs it and sends it to Regulatory Affairs, who file it with FDA.
Withdrawn pieces stayed live a median of 1.4 days, against a target of under 5 business days. Pieces live on the old label fall day by day toward 0 by Nov 1. Of the 87 impacted, 50 were found by exact text, 21 by a changed number, 3 by an old table or section reference and 13 by meaning.
The same label change, seen by the four people who carry it — what their week looked like, and what it looks like now.
Six specialist agents compare the labels, search every channel and follow each piece through; the regulatory advertising lead decides.
Compares the new label with the one in use, section by section, and explains each change in plain words with its severity for promotion.
Links each change to the claims-library entries and safety blocks that rely on the old text, and proposes retiring or re-versioning them.
Reads every live approved piece in every channel — text, images, charts and built-in safety text — and finds each passage that relies on changed label text, including paraphrases.
Proposes withdraw now, revise, safety text update or no change for each piece — with both citations, the reason and a confidence.
Turns each signed decision into tasks in every system where the piece lives, revision briefs with the exact new wording, and the statement of intent to comply.
Collects confirmations from each system, re-reads the channels to prove a withdrawn piece is gone, and re-opens anything still live.
Decides and signs. The agents propose; a named person decides.
Ask in plain words, or tell it what to change. It answers from the old and new labels, the live pieces, the claims library and every channel’s deployment list, and cites the passage behind every answer.
Which pieces still promise no lab monitoring?
7 pieces say or imply that no lab monitoring is needed — the new warning 5.4 requires liver tests at baseline and Weeks 4, 8 and 12. 3 still need your decision before Oct 9. Three use their own wording (“no lab tests needed between visits”) and were found by meaning.
Draft the statement of intent to comply
Drafted from the impact list for 21 CFR 601.12(a)(4), due Oct 9: 9 pieces withdrawn by Oct 9, 257 with safety information updated by Oct 16, 46 revised on Form 2253 by Nov 1. It commits to prominent disclosure of the new liver warning. I opened it for your signature.
What changed in the efficacy numbers?
Week-52 PASI 90 moves from 81% to 80% after the pooled re-analysis, and Table 5 is now Table 7. 14 pieces quote 81% or cite Table 5 — for example the HCP efficacy page, already revised and in MLR.
Add a rule: pause paid media within 24 hours of a safety change
Done. New rule: when a label adds a warning, paid search and display placements that carry an affected claim are paused within 24 hours, before your decision on each piece. The rule is in Settings and in the audit trail.
12 screens from the working solution, on its sample data. Pick one to see it large.
Clocks, signers, reviewers and how the agents match are settings, changed in plain words and recorded in the audit trail.
| Setting | Default | Choose from |
|---|---|---|
| Withdraw-now pieces out of use | 5 business days | 5 · 3 · 2 business days |
| Built-in safety text updated | 10 business days | 10 · 5 business days |
| Revisions republished | 30 days | 30 · 45 days |
| Statement of intent to comply | Draft on day 1, remind on day 5 | Draft on day 1, remind on day 5 · Draft on day 1, remind on day 3 |
| Withdraw, revise or update — signed by | Dana Okafor | Dana Okafor · Lena Ortiz |
| Second approval for “Not impacted” on a safety change | Lena Ortiz · Legal | Lena Ortiz (Legal) · Dr. Maya Chen (Medical) |
| Revised pieces reviewed by | Standard MLR team | Standard MLR team · Fast track · one reviewer |
| Matching | Meaning, numbers and references, drafts in MLR | Each on or off |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample brand data · “target” = the design goal, measured in the live solution · “estimated” = our estimate · “typical” = published requirement (FDA supplement approval letters ask for a statement of intent to comply within 7 days; 21 CFR 314.70(a)(4) and 601.12(a)(4)). People, companies and products named on this page are fictional — characters and sample data in the working solution.
When a product’s label changes, every live promotional piece built on the old text has to be found and withdrawn, revised or given new safety text. The Label-Change Content Impact Monitor compares the old and new label, finds every affected piece in every channel, proposes the action for each with citations, and tracks each one until it is fixed or retired.
The inventory searcher reads each piece four ways: exact claim text, changed numbers, old table or section references, and meaning. Meaning catches pieces that say the same thing in their own words — “no lab tests needed between visits” matches the retired claim “no routine laboratory monitoring is required”. It also reads text inside images and charts.
No. The agents propose; the regulatory advertising lead decides each piece and signs it electronically. Tasks open only after that signature, and clearing a flagged piece as not impacted on a safety change needs a reason and Legal’s second approval.
The completion tracker reads back from each system: document state, device sync counts, page and placement status, warehouse stock and field confirmations. A withdrawal is confirmed only when every channel shows it gone, and the task re-opens if the piece reappears.
Yes. The task writer drafts the statement of intent to comply from the impact list — what will be withdrawn, updated and revised, and by when — for the lead to sign and send to Regulatory Affairs. Revised pieces go through MLR and are listed for Form FDA 2253 at first use.
Yes. Drop in a draft label from labeling negotiations and it previews the impact against your live pieces. Nothing opens until the label is approved, but you can brief the agencies early so revisions are ready on approval day.
Your content system, websites, CRM rep emails, detail aids on rep iPads, media agency placements, the social scheduler, the print warehouse, the speaker bureau and your email platform. It reads them every morning and after every approval.
The Agentic Solution Engine builds and deploys it from your requirements and documents — your label versions, claims library, content inventory and procedure — and it goes live once every quality gate has passed. We will walk you through it on one of your own past label changes first.
The quarterly risk narrative, drafted in minutes with every figure from a live query.
1-min filmField PlaybooksEvery rep opens the right playbook for their market, built 70% faster.
1-min filmClaims ReviewEvery chargeback claim read first by agents, each verdict with its rule and evidence.
1-min filmWe’ll run Label Change Impact on one of your past label changes and your own live content.